FDA label

What is Abilify Asimtufii used for?

Abilify Asimtufii contains aripiprazole. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.

Source: DailyMed SPL label file dated 2026-10-23. Publisher page

The FDA label says: “ABILIFY ASIMTUFII is indicated: for the treatment of schizophrenia in adults; for maintenance monotherapy treatment of bipolar I disorder in adults.”

Run it in Rivvi

Which 2027 plans near you dropped or restricted Abilify Asimtufii?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Abilify Asimtufii, injection, suspension, extended release

Indications and Usage, quoted from the label by Otsuka America Pharmaceutical, Inc (NDA217006). Cross-references to other label sections are left out.

ABILIFY ASIMTUFII is indicated:

  • for the treatment of schizophrenia in adults
  • for maintenance monotherapy treatment of bipolar I disorder in adults

Source: DailyMed label, set id da4c07fd-1130-4341-bb44-63acfa4162be, version 6, effective April 4, 2025. NDC 59148-102, one of 2 listings for this product.

Questions

What is Abilify Asimtufii used for?

The FDA label says: “ABILIFY ASIMTUFII is indicated: for the treatment of schizophrenia in adults; for maintenance monotherapy treatment of bipolar I disorder in adults.”

What drug class is Abilify Asimtufii?

FDA lists aripiprazole in the Atypical Antipsychotic established pharmacologic class.

Does this page cover off-label uses or dosing?

No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.

More on Abilify Asimtufii

Try it on your own data today.

Free to start. Most teams are using it the same day.